Liquid biopsies in lung cancer: The new ambrosia of researchers

Riccardo Alessandro, Francesco Passiglia, Simona Taverna, Renza Vento, Marta Castiglia, Antonio Russo, Karen Zwaenepoel, Ignacio Gil-Bazo, Marc Peeters, David Hong, Marta Castiglia, Francesco Passiglia, Geert Baggerman, Patrick Pauwels, Anna P. Carreca, Christian Rolfo, Inge Mertens

Risultato della ricerca: Article

96 Citazioni (Scopus)

Abstract

In the last decades the approach to cancer patient management has been deeply revolutionized. We are moving from a "one-fits-all" strategy to the "personalized medicine" based on the molecular characterization of the tumor. In this new era it is becoming more and more clear that the monitoring of the disease is fundamental for the success of the treatment, thus there is the need of new biomarker discovery. More precisely in the last years the scientific community has started to use the term "liquid biopsy". A liquid biopsy is a liquid biomarker that can be easily isolated from many body fluids (blood, saliva, urine, ascites, pleural effusion, etc.) and, as well as a tissue biopsy, a representative of the tissue from which it is spread. In this review we will focus our attention on circulating tumor cells, circulating tumor DNA, exosomes and secretomes with the aim to underlie their usefulness and potential application in a clinical setting for lung cancer patient management.
Lingua originaleEnglish
pagine (da-a)539-546
Numero di pagine8
RivistaBIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
Volume1846
Stato di pubblicazionePublished - 2014

Fingerprint

Ambrosia
Lung Neoplasms
Research Personnel
Biopsy
Biomarkers
Exosomes
Circulating Neoplastic Cells
Neoplasms
Precision Medicine
Body Fluids
Pleural Effusion
Saliva
Ascites
Urine
DNA
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Genetics
  • Cancer Research

Cita questo

Liquid biopsies in lung cancer: The new ambrosia of researchers. / Alessandro, Riccardo; Passiglia, Francesco; Taverna, Simona; Vento, Renza; Castiglia, Marta; Russo, Antonio; Zwaenepoel, Karen; Gil-Bazo, Ignacio; Peeters, Marc; Hong, David; Castiglia, Marta; Passiglia, Francesco; Baggerman, Geert; Pauwels, Patrick; Carreca, Anna P.; Rolfo, Christian; Mertens, Inge.

In: BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, Vol. 1846, 2014, pag. 539-546.

Risultato della ricerca: Article

Alessandro, R, Passiglia, F, Taverna, S, Vento, R, Castiglia, M, Russo, A, Zwaenepoel, K, Gil-Bazo, I, Peeters, M, Hong, D, Castiglia, M, Passiglia, F, Baggerman, G, Pauwels, P, Carreca, AP, Rolfo, C & Mertens, I 2014, 'Liquid biopsies in lung cancer: The new ambrosia of researchers', BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, vol. 1846, pagg. 539-546.
Alessandro, Riccardo ; Passiglia, Francesco ; Taverna, Simona ; Vento, Renza ; Castiglia, Marta ; Russo, Antonio ; Zwaenepoel, Karen ; Gil-Bazo, Ignacio ; Peeters, Marc ; Hong, David ; Castiglia, Marta ; Passiglia, Francesco ; Baggerman, Geert ; Pauwels, Patrick ; Carreca, Anna P. ; Rolfo, Christian ; Mertens, Inge. / Liquid biopsies in lung cancer: The new ambrosia of researchers. In: BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER. 2014 ; Vol. 1846. pagg. 539-546.
@article{90bd2c21e9ab4ffe84a40c5ec76d0562,
title = "Liquid biopsies in lung cancer: The new ambrosia of researchers",
abstract = "In the last decades the approach to cancer patient management has been deeply revolutionized. We are moving from a {"}one-fits-all{"} strategy to the {"}personalized medicine{"} based on the molecular characterization of the tumor. In this new era it is becoming more and more clear that the monitoring of the disease is fundamental for the success of the treatment, thus there is the need of new biomarker discovery. More precisely in the last years the scientific community has started to use the term {"}liquid biopsy{"}. A liquid biopsy is a liquid biomarker that can be easily isolated from many body fluids (blood, saliva, urine, ascites, pleural effusion, etc.) and, as well as a tissue biopsy, a representative of the tissue from which it is spread. In this review we will focus our attention on circulating tumor cells, circulating tumor DNA, exosomes and secretomes with the aim to underlie their usefulness and potential application in a clinical setting for lung cancer patient management.",
author = "Riccardo Alessandro and Francesco Passiglia and Simona Taverna and Renza Vento and Marta Castiglia and Antonio Russo and Karen Zwaenepoel and Ignacio Gil-Bazo and Marc Peeters and David Hong and Marta Castiglia and Francesco Passiglia and Geert Baggerman and Patrick Pauwels and Carreca, {Anna P.} and Christian Rolfo and Inge Mertens",
year = "2014",
language = "English",
volume = "1846",
pages = "539--546",
journal = "Biochimica et Biophysica Acta - Reviews on Cancer",
issn = "0304-419X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Liquid biopsies in lung cancer: The new ambrosia of researchers

AU - Alessandro, Riccardo

AU - Passiglia, Francesco

AU - Taverna, Simona

AU - Vento, Renza

AU - Castiglia, Marta

AU - Russo, Antonio

AU - Zwaenepoel, Karen

AU - Gil-Bazo, Ignacio

AU - Peeters, Marc

AU - Hong, David

AU - Castiglia, Marta

AU - Passiglia, Francesco

AU - Baggerman, Geert

AU - Pauwels, Patrick

AU - Carreca, Anna P.

AU - Rolfo, Christian

AU - Mertens, Inge

PY - 2014

Y1 - 2014

N2 - In the last decades the approach to cancer patient management has been deeply revolutionized. We are moving from a "one-fits-all" strategy to the "personalized medicine" based on the molecular characterization of the tumor. In this new era it is becoming more and more clear that the monitoring of the disease is fundamental for the success of the treatment, thus there is the need of new biomarker discovery. More precisely in the last years the scientific community has started to use the term "liquid biopsy". A liquid biopsy is a liquid biomarker that can be easily isolated from many body fluids (blood, saliva, urine, ascites, pleural effusion, etc.) and, as well as a tissue biopsy, a representative of the tissue from which it is spread. In this review we will focus our attention on circulating tumor cells, circulating tumor DNA, exosomes and secretomes with the aim to underlie their usefulness and potential application in a clinical setting for lung cancer patient management.

AB - In the last decades the approach to cancer patient management has been deeply revolutionized. We are moving from a "one-fits-all" strategy to the "personalized medicine" based on the molecular characterization of the tumor. In this new era it is becoming more and more clear that the monitoring of the disease is fundamental for the success of the treatment, thus there is the need of new biomarker discovery. More precisely in the last years the scientific community has started to use the term "liquid biopsy". A liquid biopsy is a liquid biomarker that can be easily isolated from many body fluids (blood, saliva, urine, ascites, pleural effusion, etc.) and, as well as a tissue biopsy, a representative of the tissue from which it is spread. In this review we will focus our attention on circulating tumor cells, circulating tumor DNA, exosomes and secretomes with the aim to underlie their usefulness and potential application in a clinical setting for lung cancer patient management.

UR - http://hdl.handle.net/10447/103012

M3 - Article

VL - 1846

SP - 539

EP - 546

JO - Biochimica et Biophysica Acta - Reviews on Cancer

JF - Biochimica et Biophysica Acta - Reviews on Cancer

SN - 0304-419X

ER -